RxDoctor Payments Data

Amy Wooldridge, MD

Internal Medicine · Greenfield, INNPI 1386624070

Payments from drug & device makers

$1,981in general payments, 2019–2025

Across 106 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$194
  • Novo Nordisk$193
  • Arbor Pharmaceuticals, Inc.$168
  • Amgen$149
  • AstraZeneca$127
  • Abbott$92
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$1,981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,981 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$168,139
Medicare patients
175
Services billed
6,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$78,927
OzempicSemaglutide36$53,664
JardianceEmpagliflozin27$41,908
RybelsusSemaglutide24$39,531
FarxigaDapagliflozin Propanediol46$34,810
XareltoRivaroxaban33$27,651
TrulicityDulaglutide19$26,741
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,195
JanuviaSitagliptin Phosphate11$12,355
AbrysvoRsv Vacc, Pref A And Pref B/Pf35$11,108
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,706
ShingrixVaricella-Zoster Ge/As01b/Pf31$6,802
Lidocaine24$4,991
Duloxetine Hcl134$3,765
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$193$93,19460 claims
PfizerEliquis, Abrysvo$69$90,03599 claims
AstraZenecaFarxiga, Breztri Aerosphere$127$48,00557 claims
Boehringer IngelheimJardiance$89$41,90827 claims
Lilly USA, LLCTrulicity$28$26,74119 claims
GSKTrelegy Ellipta, Shingrix$61$15,50744 claims
AbbVieSynthroid$194$1,90325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Greenfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →